Recent Updates
Recently added Catalysts
BLTE Positive Sentiment

Belite Bio to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference

Thursday, November 30, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Belite Bio, Inc. (NASDAQ: BLTE) has announced its participation in the Benchmark Company’s 12th Annual Discovery One-on-One Investor Conference, scheduled for December 7, 2023, at the New York Athletic Club. This event represents an opportunity for Belite to engage directly with investors and discuss its clinical-stage biopharmaceutical developments targeting degenerative retinal diseases. Interested investors can register for the conference and request one-on-one meetings with the company's management.
Price reaction · baseline $38.21 (2023-11-29 close) · hit after-hours · clean, no other BLTE news in the window
day 0 close
+10.1%
day 1 · peak
+10.2%
day 3
+8.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a prominent investor conference indicates increasing investor interest.
  • Showcases Belite Bio's focus on addressing unmet medical needs in retinal diseases.
  • Opportunity for management to connect with potential investors.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+33%
120-day peak, hindsight
Typical move
6.1%
average across 7 past catalysts
Lead asset
Tinlarebant
Phase 3 · Geographic Atrophy

Full Press Release Details

SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will be participating at the Benchmark Company’s 12th Annual Discovery One-on-One Investor Conference to be held Thursday, December 7, 2023, at the New York Athletic Club in New York City.
To schedule a one-on-one meeting with management, you may submit your request online via the link provided upon registration. To register for the conference, please visit https://www.meetmax.com/sched/event_99181/investor_reg_new.html?attendee_role_id=INVESTOR.
Media and Investor Relations Contact:

Frequently Asked Questions

What is Belite Bio, Inc. focused on?

Belite Bio focuses on developing therapies for degenerative retinal diseases.

When is the Benchmark Company’s investor conference?

The conference is on December 7, 2023.

Where will the investor conference take place?

It will be held at the New York Athletic Club in New York City.

How can I schedule a meeting with Belite Bio's management?

You can schedule a meeting online after registering for the conference.

Who should I contact for media inquiries about Belite Bio?

Contact belite@argotpartners.com for media and investor relations.

ShareAdd on Google
Tags: BLTE Viatris Investor Conferences Healthcare Belite Bio retinal diseases biopharmaceutical Benchmark Company
Last updated: Nov 30, 2023

Biotech snapshot

Lead asset
TinlarebantPhase 3
Geographic Atrophy →

Catalyst track record

+33%
best trade around BLTE's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for BLTE.

See every catalyst's timing & PoA →